# COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis

> **NCT02964403** · PHASE4 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 2700 (estimated)

## Conditions studied

- Pancreatitis, Acute

## Interventions

- **DRUG:** Cox-2
- **DRUG:** Indomethacin

## Key facts

- **NCT ID:** NCT02964403
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-12
- **Primary completion:** 2018-02
- **Final completion:** 2018-08
- **Target enrollment:** 2700 (ESTIMATED)
- **Last updated:** 2016-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02964403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02964403, "COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02964403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*